Based on the WisdomTree BioRevolution UCITS ETF - USD Acc stock forecast from 0 analysts, the average analyst target price for WisdomTree BioRevolution UCITS ETF - USD Acc is not available over the next 12 months. WisdomTree BioRevolution UCITS ETF - USD Acc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of WisdomTree BioRevolution UCITS ETF - USD Acc is Very Bearish, which is based on 0 positive signals and 3 negative signals. At the last closing, WisdomTree BioRevolution UCITS ETF - USD Acc’s stock price was EUR 16.00. WisdomTree BioRevolution UCITS ETF - USD Acc’s stock price has changed by -0.68% over the past week, +0.63% over the past month and +10.64% over the last year.
No recent analyst target price found for WisdomTree BioRevolution UCITS ETF - USD Acc
No recent average analyst rating found for WisdomTree BioRevolution UCITS ETF - USD Acc
Company Overview WisdomTree BioRevolution UCITS ETF - USD Acc
Stock Target Advisor's fundamental analysis for WisdomTree BioRevolution UCITS ETF - USD Acc's stock is Very Bearish.
WRNA:XETRA stock's dividend yield is 1.09%.
Our analysis grades WRNA:XETRA stock's dividend yield at F. This means that WRNA:XETRA stock's dividend yield is above 9% of the stocks in the Others sector in the XETRA exchange.
Based on this WRNA:XETRA may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on WRNA:XETRA's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on WRNA:XETRA's stock to indicate if its overvalued.
The last closing price of WRNA:XETRA's stock was EUR 16.00.
The most recent market capitalization for WRNA:XETRA is EUR 2.77M.
Unfortunately we do not have enough analyst data on WRNA:XETRA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains WisdomTree BioRevolution UCITS ETF - USD Acc's stock.
As per our most recent records WisdomTree BioRevolution UCITS ETF - USD Acc has 0 Employees.
Sorry we do not have any infomation available on WisdomTree BioRevolution UCITS ETF - USD Acc's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Stock Target Advisor's fundamental analysis for WisdomTree BioRevolution UCITS ETF - USD Acc's stock is Very Bearish.
WRNA:XETRA stock's dividend yield is 1.09%.
Our analysis grades WRNA:XETRA stock's dividend yield at F. This means that WRNA:XETRA stock's dividend yield is above 9% of the stocks in the Others sector in the XETRA exchange.
Based on this WRNA:XETRA may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on WRNA:XETRA's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on WRNA:XETRA's stock to indicate if its overvalued.
The last closing price of WRNA:XETRA's stock was EUR 16.00.
The most recent market capitalization for WRNA:XETRA is EUR 2.77M.
Unfortunately we do not have enough analyst data on WRNA:XETRA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains WisdomTree BioRevolution UCITS ETF - USD Acc's stock.
As per our most recent records WisdomTree BioRevolution UCITS ETF - USD Acc has 0 Employees.
Sorry we do not have any infomation available on WisdomTree BioRevolution UCITS ETF - USD Acc's address.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for WRNA:XETRA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
